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Selenium,	a	trace	element	that	is	fundamental	to	human	health,	is	incorporated	into	some	proteins	as	seleno-
cysteine	(Sec),	generating	a	family	of	selenoproteins.	Sec	incorporation	is	mediated	by	a	multiprotein	complex	
that	includes	Sec	insertion	sequence–binding	protein	2	(SECISBP2;	also	known	as	SBP2).	Here,	we	describe	
subjects	with	compound	heterozygous	defects	in	the	SECISBP2	gene.	These	individuals	have	reduced	synthe-
sis	of	most	of	the	25	known	human	selenoproteins,	resulting	in	a	complex	phenotype.	Azoospermia,	with	
failure	of	the	latter	stages	of	spermatogenesis,	was	associated	with	a	lack	of	testis-enriched	selenoproteins.	
An	axial	muscular	dystrophy	was	also	present,	with	features	similar	to	myopathies	caused	by	mutations	in	
selenoprotein	N	(SEPN1).	Cutaneous	deficiencies	of	antioxidant	selenoenzymes,	increased	cellular	ROS,	and	
susceptibility	to	ultraviolet	radiation–induced	oxidative	damage	may	mediate	the	observed	photosensitivity.	
Reduced	levels	of	selenoproteins	in	peripheral	blood	cells	were	associated	with	impaired	T	lymphocyte	prolif-
eration,	abnormal	mononuclear	cell	cytokine	secretion,	and	telomere	shortening.	Paradoxically,	raised	ROS	
in	affected	subjects	was	associated	with	enhanced	systemic	and	cellular	insulin	sensitivity,	similar	to	findings	
in	mice	lacking	the	antioxidant	selenoenzyme	glutathione	peroxidase	1	(GPx1).	Thus,	mutation	of	SECISBP2	is	
associated	with	a	multisystem	disorder	with	defective	biosynthesis	of	many	selenoproteins,	highlighting	their	
role	in	diverse	biological	processes.
Introduction
Selenium is an essential trace element that is fundamental to 
human health. Its biological role is mediated principally by 
cotranslational incorporation of selenocysteine (Sec; the 21st 
amino acid) into selenium-containing proteins. Sec-containing 
proteins represent a diverse group, their functions ranging from 
metabolism of thyroid hormones (deiodinases), to removal of 
cellular ROS (glutathione peroxidase [GPx] types 1, 2, 3, 4, and 6 
and thioredoxin reductase [TrxR] types 1, 2, and 3; ref. 1), to 
reduction of oxidized methionines in proteins (selenoprotein X; 
also referred to as MSRB1), to thioredoxin-dependent ribonu-
cleotide reductase activity for DNA synthesis (2), to transport 
and delivery of selenium to peripheral tissues (selenoprotein P 
[SEPP]), to protein folding and ER stress (Sep-15, SELM, and 
SELS). Moreover, the precise function of some Sec-containing 
proteins remains unknown (SELO, SELV, SEPW, SELK, SELH, 
SELI, and SELT; refs. 3–5).
A molecular mechanism that is highly conserved from Archae-
bacteria to higher eukaryotes mediates the translational incorpo-
ration of Sec during selenoprotein synthesis. Interaction of a stem-
loop RNA structure (Sec insertion sequence [SECIS] element), 
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usually located in the 3′–untranslated region of selenoprotein 
mRNAs (6), with a multiprotein complex, which includes SECIS-
binding protein 2 (SECISBP2; referred to herein as SBP2; ref. 7), 
leads to Sec incorporation mediated by a specific selenocysteyl-
transfer RNA (tRNA[Ser]Sec) at UGA codons (4, 8). Failure of this 
mechanism can result in miscoding of the UGA as a stop codon 
and, depending on its location in the mRNA, the transcript may 
undergo nonsense-mediated decay (NMD). Variable affinity of 
SBP2 interaction with SECIS elements in different genes likely con-
tributes to a hierarchy of differentially diminished selenoprotein 
Figure 1
Genotypes and biochemical phenotypes in 2 families with defects in SECISBP2. (A) Schematic representations of the coding exons of SECISBP2 
(top) showing the location of aberrantly spliced variant transcripts (P1, green; P2, orange), and the major domains of SBP2 (bottom) showing the 
frameshift premature stop (P1, blue, fs255X) and missense (P2, red, C691R) mutations. NLS, nuclear localization signal; NES, nuclear export 
signal; L7Ae module, domain homolog to RNA-binding domain of L7Ae; M1, M233, M300, position of alternate methionine transcription initiation 
sites, with M1 yielding full-length wild-type SBP2 protein. (B and C) Pedigrees of families 1 (B) and 2 (C) showing genotypes (as described in A); 
squares and circles represent male and female family members, respectively, and arrows/filled symbols denote probands. Below, Western blot-
ting for SEPP and GPx3 in plasma of both probands and family members. Black arrows indicate specific bands; white arrows denote nonspecific 
bands. Albumin was used as a loading control. (D) PBMCs from P1 and P2 demonstrate defective selenoprotein synthesis. Selenoprotein biosyn-
thesis in PBMCs was assessed using 75Se labeling as described in Methods. 35S-Met labeling confirmed comparable protein loading. C, control 
subject (age- and sex-matched to P1). (E) Fibroblasts from P1 and P2 lack full-length SBP2. Whole cell lysates from primary skin fibroblasts were 
Western blotted for full-length (FL) SBP2 (arrow) with actin as a loading control. Age- and sex-matched control subjects were used.
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synthesis when SBP2 levels are reduced (9). The architecture of 
SECISBP2 is highly complex, with alternative splicing of the gene 
to generate multiple transcripts with internal methionine residues 
capable of directing synthesis of shorter protein isoforms (10).
Here, we describe affected individuals from 2 families, identi-
fied on the basis of elevated circulating thyroxine (T4) levels, but 
low levels of selenium and selenoproteins (SEPP and GPx3). Their 
biochemical profile, suggestive of a broader deficiency of deio-
dinase enzymes as well as other selenoproteins, was analogous 
to the phenotype of childhood cases with defects in SECISBP2, 
reported previously (11, 12). Consistent with this, the probands 
were compound heterozygous for mutations in the SECISBP2 
coding region together with missplicing of transcripts derived 
from the other allele. In our affected subjects, we observed clini-
cal (azoospermia, axial muscular dystrophy, skin photosensitiv-
ity, abnormal immune cell function, and marked insulin sensi-
tivity) and cellular (increased ROS production, membrane lipid 
peroxidation and oxidative DNA damage, and accelerated telo-
mere shortening) features that could be directly attributed to 
loss of selenoprotein function. We have also documented cellular 
deficiencies of additional members of the selenoproteome (e.g., 
SELH, SELT, SELW, and SELI) whose function is unknown. Our 
observations define a multisystem disorder involving the defec-
tive biosynthesis of many selenoproteins.
Results
Case histories. Proband 1 (P1), a male adult, presented at age 35 years 
with symptoms including fatigue, muscle weakness, and severe 
Raynaud disease (digital vasospasm). Investigations including 
thyroid function tests showed elevated free T4 (FT4, 41 pmol/l; 
normal range [NR], 9–20 pmol/l) levels, but normal levels of free 
triiodothyronine (FT3, 3.8 pmol/l; NR, 3–7.5 pmol/l) and thy-
roid-stimulating hormone (TSH, 0.49 mU/l; NR, 0.4–4 mU/l). In 
childhood, both motor and speech developmental milestones were 
delayed, requiring speech therapy. Despite treatment (myringoto-
mies) for secretory otitis media at 6 years of age, hearing problems 
persisted. Walking and running remained problematic in adoles-
cence, with genu valgus and external rotation of the hip requir-
ing orthotic footwear. At the age of 13 years, symptoms of marked 
sun photosensitivity were noted with abnormal UV responses on 
phototesting, although no cause was established. Pubertal devel-
opment was normal, but at the age of 15 years, he developed unilat-
eral testicular torsion requiring orchidectomy and fixation of the 
remaining testis. His final stature (1.66 m) was close to the mean 
value (1.69 m) expected from parental heights (father, 1.77 m; 
mother, 1.61 m), but on the ninth centile. Ongoing problems in 
adulthood included primary infertility, skin photosensitivity, 
muscle weakness, impaired hearing, and rotatory vertigo.
Proband 2 (P2), a male child, presented at age 2 years with pro-
gressive failure to thrive in infancy, which led to a diagnosis of 
eosinophilic colitis for which he has since been treated with aza-
thioprine and sodium cromoglycate. When fasting (e.g., overnight), 
he would develop nonketotic hypoglycemia with low insulin levels 
and required supplemental enteral nutrition to prevent this. At 
age 3.6 years, mild, global developmental delay and short stature 
prompted investigation that showed elevated FT4 (44 pmol/l; NR, 
12–22 pmol/l), low FT3 (1.9 pmol/l; NR, 5.2–10.2 pmol/l), and nor-
mal TSH (2.9 mU/l; NR, <6 mU/l) levels. Additional features in this 
index case included muscle weakness and mild bilateral high-fre-
quency hearing loss. Normalization of FT3 levels following com-
mencement of liothyronine treatment has been associated with 
improvement in linear growth, speech, and neurodevelopment.
Compound heterozygous SECISBP2 defects. We identified 2 subjects 
harboring SECISBP2 mutations (Figure 1, A–C), with case histories 
and biochemical features similar to 3 previously described cases 
(11, 12). Both P1 and P2 showed markedly raised T4 with normal or 
reduced T3 levels, signifying impaired conversion of T4 to T3 medi-
ated by Sec-containing deiodinase enzymes (Table 1). Circulating 
selenium levels were very low, reflecting markedly reduced expres-
sion of plasma GPx3 and SEPP (Figure 1, B and C), the major circu-
lating proteins contributing to levels of this element. Furthermore, 
rbc GPx1 levels were also low or undetectable (Table 1). This com-
bination of biochemical abnormalities suggested a global defect in 
selenoprotein synthesis.
We therefore sequenced SECISBP2 at both genomic and cDNA 
levels, identifying compound heterozygous abnormalities in both 
probands: P1 was heterozygous for a paternally inherited frame-
shift/premature stop mutation in exon 5 ([T668ΔT]fs.223[stop255]; 
referred to herein as fs255X) on 1 allele, together with a splicing 
defect causing misincorporation of additional intronic sequence 
between exons 6 and 7 on the other allele (Figure 1, A and B, and 
Supplemental Figure 1, A and B; supplemental material available 
online with this article; doi:10.1172/JCI43653DS1). Such miss-
plicing may be linked to a single nucleotide change at –155 bp in 
this intron, which occurred de novo in P1 (Supplemental Figure 
1B). P2 was heterozygous for the maternally inherited missense 
mutation C691R, changing a highly conserved cysteine residue 
in the RNA binding domain of SBP2, together with a paternally 
Table 1
Biochemical profiles in both probands and unaffected family members
Parameter	 Reference	range(s)	 Family	1	 Family	2
	 	 Father	 Brother	 Index	 Mother	 Father	 Brother	 Index	 Mother
Age (yr)  68 38 36 59 32 8 4 30
TSH (mU/l) Adult, 0.4–4; child, <6 0.42 1.33 0.49 1.76 1.34 1.12 1.10 6.52
FT4 (pmol/l) Adult, 9–20; child, 12–22 15.4 16.7 41.1 14.7 15.4 15.5 35.0 12.8
FT3 (pmol/l) Adult, 3–7.5; child, 5.2–10.2 6.4 7.0 3.8 6.3 6.4 NA 2.3 6.2
rT3 (ng/ml) 0.1–0.35 0.30 0.25 1.32 0.40 0.24 NA 1.20 0.30
Plasma Se (μmol/l) >0.8 1.10 1.06 0.14 1.30 1.00 NA 0.11 0.82
rbc GPx1 (U/gHb) >20 32.6 44.3 5.4 71.4 25.0 NA UD 22.0
NA, not available; rT3, reverse T3; Se, selenium; UD, undetectable. Abnormal results are shown in bold.
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derived defect generating aberrantly spliced SBP2 transcripts 
(lacking either exons 2–4 or exons 3 and 4; referred to herein as 
Δ2-3-4 and Δ3-4, respectively; Figure 1, A and C, and Supplemental 
Figure 1, D and E). The aberrantly spliced SBP2 transcripts were 
not found in RNA derived from 100 normal alleles; likewise, the 
single nucleotide changes in SECISBP2 were absent in 200 normal 
alleles sequenced (data not shown). No mutations, but several 
SNPs in introns between exons 1 and 5 (Supplemental Figure 1E), 
were identified in P2, but whether the latter account for his SBP2 
missplicing is not known. The heterozygous father and brother of 
P1 and father of P2 lacked a discernible biochemical phenotype, 
with normal biosynthesis of 75Se-labeled selenoproteins in PBMCs, 
but the mother of P2 (C691R mutation) did show slightly reduced 
radiolabeled selenoprotein levels in PBMCs with borderline-low 
circulating selenium levels (Figure 1D and Table 1).
Each of the SECISBP2 mutations in P1 is predicted to terminate 
the transcript prematurely (Supplemental Figure 1, A and B). 
Consistent with this, Western blotting of his fibroblasts showed 
lack of full-length SBP2 protein expression (Figure 1E). Surpris-
ingly, expression of full-length SBP2 protein in fibroblasts from 
P2 was also absent. We anticipated that the paternally derived, 
shorter SBP2 transcripts (Δ2-3-4 and Δ3-4) in P2 would not yield 
a full-length protein product; unexpectedly, however, we found 
that the stability of the maternally inherited mutant (C691R) 
SBP2 protein was reduced as a result of enhanced proteasomal 
degradation (Supplemental Figure 1F). Modeling of the SBP2 
RNA binding region with a similar functional domain from the 
L7Ae sRNA protein may provide an explanation for this. C691, 
which is highly conserved in different species, is located within 
a hydrophobic core, and its replacement with a charged arginine 
residue is likely to disrupt protein folding and perhaps stability 
(Supplemental Figure 1G). Thus, this combination of defects in 
P2 is also likely to preclude significant synthesis of intact SBP2.
Despite their lack of full-length SBP2 protein expression, 75Se 
labeling studies of PBMCs from both P1 and P2 indicated markedly 
reduced, but not completely abolished, selenoprotein synthesis 
(Figure 1D). This suggests that some functional SBP2 is generated 
in both P1 and P2 in vivo, as has been recently documented in a 
case with a homozygous null SECISBP2 mutation (12). Consistent 
with this hypothesis, cells transfected with a minigene construct 
containing the fs255X SECISBP2 mutation found in P1 did express 
shorter SBP2 isoforms, likely initiating from alternative ATGs 
(M233 and M300) downstream of the stop codon (Supplemen-
tal Figure 1C). Likewise, although the SECISBP2 splicing defects 
(Δ2-3-4 and Δ3-4) found in P2 are also predicted to terminate 
translation prematurely, protein synthesis can be reinitiated from 
these downstream methionine residues (Supplemental Figure 1E). 
Such truncated SBP2 isoforms in P1 and P2 would retain the car-
boxyterminal region of the protein, containing key domains medi-
ating ribosome interaction, RNA binding, and Sec incorporation 
functions (Figure 1A). Indeed, previous studies have shown that an 
SBP2 truncation mutant containing these domains is capable of 
mediating Sec incorporation (13).
Azoospermia with spermatogenic maturation arrest. Following slow 
growth in early childhood, later pubertal development in P1 was 
normal, despite unilateral orchidectomy at age 15 years following 
an episode of testicular torsion. Primary infertility in adulthood 
prompted further investigation, with 2 separate analyses of semen 
from P1 showing complete azoospermia despite the presence of a 
sonographically normal, remaining testis (data not shown). Normal 
Figure 2
Spermatogenic maturation arrest 
associated with deficiencies of tes-
tis-expressed selenoproteins. H&E 
images (original magnification, ×40) 
of a seminiferous tubule from a nor-
mal subject (A) and P1 (G). Circled 
areas (A) from normal testis show 
mature spermatozoa. Spermatids 
and spermatozoa were absent, but 
with preservation of spermatogonia 
and spermatocytes, in P1 (G). IHC 
showed virtual absence of mGPx4, 
TGR, and SELV immunoreactivity in 
testis from P1 (H–J) compared with 
their expression in later stages of 
spermatogenesis in a normal subject 
(B, D, and F). Expanded images (C 
and E; original magnification, ×60) 
also highlighted mGPx4 and TGR 
expression in the midpiece of normal 
spermatozoa (arrows). Scale bars: 
20 μm (A, B, D, and F–J); 5 μm (C 
and E). Western blotting of seminal 
plasma from a normal control subject 
and P1 using antibodies for mGPx4 
(K), TGR (L), and SELV (M), with 
actin (N) as a loading control. Black 
arrows indicate specific bands; white 
arrow denotes nonspecific band.
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circulating testosterone (24 nmol/l; NR, 8–32 nmol/l), but signifi-
cantly reduced Inhibin B (36 pg/ml; NR, 160–215 pg/ml), levels in 
P1 suggested preservation of Leydig cell but impaired Sertoli/germ 
cell function. Histological examination of the testis removed previ-
ously in adolescence showed maturation arrest in spermatogenesis, 
with preservation of spermatogonia and spermatocytes in the germ 
cell lining of the seminiferous tubules, but an absence of the mature 
stage spermatids and spermatozoa (Figure 2G). Western blot analysis 
of azoospermic seminal fluid from P1 showed markedly reduced lev-
els of the known testis-enriched selenoproteins mitochondrial GPx4 
(mGPx4), thioredoxin-glutathione reductase (TGR; also referred to 
as TXNRD3), and selenoprotein V (SELV) compared with normal, 
seminal plasma (Figure 2, K–M). Immunohistochemistry (IHC) of 
normal testis confirmed that mGPx4, TGR, and SELV expression 
was largely confined to later stages of spermatogenesis, with mGPx4 
and TGR being particularly localized to the midpiece of normal 
spermatozoa (Figure 2, C and E, arrows); in contrast, these proteins 
were virtually absent in the testis of P1 (Figure 2, H–J).
Axial muscular dystrophy similar to SEPN1-related myopathies. A his-
tory of reduced exercise tolerance and difficulties with daily activi-
ties of life (e.g., lifting and climbing stairs) in P1 prompted further 
investigation, which confirmed reduced aerobic exercise capacity 
(50% of predicted), reduced lung vital capacity (3.3 l; NR, 3.5–5.4 l), 
and diminished muscle strength affecting predominantly axial and 
neck muscle groups together with elevated serum creatine kinase 
(CK) levels (896 U/l; NR, 24–195 U/l), which isoenzyme electro-
phoresis showed to be skeletal muscle–derived (CK-MM). Imaging 
showed marked loss of normal spinal curvature (Figure 3A) with 
connective tissue and fatty infiltration of paraspinal muscles and 
adductor and sartorius muscle groups (Figure 3, B and C) closely 
resembling the selective pattern of muscle involvement previously 
reported in rigid spine muscular dystrophy (RSMD1), a disorder 
associated with defects in the selenoprotein N (SEPN1) gene (14, 
15). Biopsy of his quadriceps muscle showed marked predominance 
of type 1 oxidative fibers (P1, 85%; normal, 35%), with occasional 
areas of sarcomere disorganization termed minicores — features 
that resembled muscle histology from a patient with RSMD1 with 
a SEPN1 mutation (Figure 4, A–F). P2 also showed clinical features 
(delayed milestones, hypotonia, mild proximal and axial weakness, 
early lumbar spinal rigidity, mild facial weakness, and nasal voice) 
and abnormal muscle imaging (fatty infiltration of adductors and 
Sartorius; Figure 3C) suggestive of an early myopathy, with remark-
able similarity to the pattern of selective involvement documented 
in RSMD1 (14). Consistent with the similarity of their muscle phe-
notypes to SEPN1-related myopathies, Western blotting of dermal 
fibroblasts from P1 and P2 showed markedly reduced protein levels 
of selenoprotein N (SELN), comparable to cells from an unrelated 
RSMD1 case harboring a SEPN1 mutation (Figure 4G).
Cutaneous photosensitivity and enhanced UV-mediated oxidative damage. 
At age 13 years, following a history of skin reddening and blister-
ing upon sun exposure, abnormal cutaneous photosensitivity was 
first documented in P1. Such symptoms persist into adulthood, 
necessitating constant use of high-strength sunblock. Repeat test-
ing confirmed that P1 remained abnormally photosensitive, with 
exposure to UVA irradiation (350 nm), even at a low dose (e.g., 
10 J/cm2), eliciting an abnormally rapid erythematous skin 
response within 90 minutes (Figure 5A), whereas normal subjects 
usually respond only at higher doses and after 24 hours.
IHC showed markedly reduced expression of GPx1, particu-
larly in the basal cell layer of the epidermis, in P1 (Figure 5B). 
TrxR enzyme activity in his skin biopsy was much lower than in 
control tissue (Figure 5C); expression of methionine-sulfoxide 
reductase B (MSRB), which catalyzes the reduction of ROS-
induced methionine sulfoxides in proteins back to L-methionine 
(16), in his dermal fibroblasts was significantly reduced (Figure 
5D). Consistent with deficiency of such antioxidant selenoen-
zymes, dermal fibroblasts from P1 showed more endogenous 
H2O2 production than control cells and greater accumulation of 
other ROS species following exogenous H2O2 exposure (Figure 6, 
A and B), confirming decreased cellular antioxidant capacity.
Figure 3
Radiological features similar to 
SEPN1-related myopathies. (A) 
Sagittal T2-weighted MRI of the 
cervical and upper thoracic spine 
in a control subject and P1, show-
ing loss of normal spinal curvature 
similar to that seen in RSMD1. (B) 
Coronal and cross-sectional T1-
weighted MRI of the paraspinal 
region of P1 showing connective 
tissue/fatty infiltration of paraspi-
nal (P-S) with sparing of psoas 
muscles. (C) Cross-sectional T1-
weighted MRI at the mid-thigh 
level in P1 revealed connec-
tive tissue/fatty infiltration in the 
adductor and sartorius muscles, 
but with relative sparing of other 
muscle groups. Similar but less 
marked changes were already evi-
dent in P2. S, sartorius; G, gracilis; 
A, adductors; H, hamstrings; Q, 
quadriceps.
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DNA damage is a known consequence of increased cellular 
ROS and includes single-strand breaks (SSBs) as well as modifi-
cation of DNA nucleobases to form 8-oxo-7,8-dihydroguanine 
(8-oxoGua). The cellular response to DNA damage includes nuclear 
accumulation of phosphorylated histone H2AX (γH2AX; ref. 17). 
Alkaline comet assay quantified much greater DNA damage in 
dermal fibroblasts from P1: SSBs and 8-oxoGua, which was sig-
nificantly enhanced following exposure of his cells to H2O2 (Figure 
6C). Direct immunofluorescence of untreated fibroblasts from P1 
showed elevated 8-oxoGua, comparable to H2O2-treated control 
cells, with further enhancement following H2O2 exposure (Figure 
6D), and similar observations were made with nuclear γH2AX foci 
in his cells (Figure 6E). Measurements over a longer time frame in 
comet assays indicated that elevated DNA damage was not caused 
by failure of DNA repair pathways (Supplemental Figure 2B).
Lipid peroxidation is another well-recognized consequence of 
oxidative stress. Using the redox-sensitive dye BODIPY 581/591 
C11, we quantified increased membrane lipid peroxidation in 
untreated fibroblasts from P1, which was ameliorated by pre-
treatment with α-tocopherol, a known membrane antioxidant 
(Figure 7A). Significantly, exposure of his dermal fibroblasts to 
UV irradiation markedly increased levels of both lipid peroxida-
tion (Figure 7A) and DNA damage as assessed by comet assay 
(Figure 7B) compared with control cells.
Figure 5
Cutaneous photosensitivity and selenoenzyme deficiency. (A) Reddening of skin in P1 90 minutes after exposure to graded doses (10−40 J/cm2) 
of UVA radiation (350 nm). The highest dose (57 J/cm2) was not tested because of the markedly abnormal responses seen with lower exposure 
levels. (B) Images (original magnification, ×20) showing markedly reduced GPx1 immunoreactivity (especially basal cell layer) in epidermis from P1 
compared with a control subject. Scale bars: 50 μm. (C) Reduced TrxR activity in skin from P1. TrxR activity was determined in skin biopsy tissue 
from P1 and a sex- and age-matched control subject. (D) Reduced MSRB expression in dermal fibroblasts from P1 and P2. Whole cell lysates of 
fibroblasts from P1 and P2 and 2 age- and sex-matched controls were Western blotted for MSRB (arrow), with actin as a loading control.
Figure 4
Histological features similar to SEPN1-related myop-
athies are associated with reduced selenoprotein N 
expression. Muscle biopsy confirmed histological 
appearances similar to those found in a patient har-
boring a known SEPN1 mutation. Sections of quad-
riceps from P1 were stained with (A) H&E, showing 
39% myofibers with internally located nuclei; (B) 
ATPase (pH 4.6), showing predominance of dark 
staining Type 1 fibers (~80%) and absence of type 
2B fibers; and (C) NADH-TR, revealing occasional 
minicores (arrow) and a rare atrophic fiber. Compa-
rable sections from a SEPN1 mutation carrier are 
shown (D–F). Original magnification, ×10 (A and D); 
×5 (B and E); ×20 (C and F). (G) Reduced SELN 
expression in fibroblasts from P1 and P2, compara-
ble to cells from a known RSMD1 subject. Whole cell 
lysates of primary skin fibroblasts from P1 and P2, 
control subjects (C1–C3), and a RSMD1 patient with 
a known SEPN1 mutation were Western blotted for 
SELN expression, with GAPDH as a loading control. 
Arrow denotes the specific SELN band.
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Figure 6
Impaired antioxidant defence in dermal fibroblasts. Endogenous H2O2 production by fibroblasts from P1 (A) and P2 (F) and age- and sex-matched 
controls was assayed using a specific indicator, as described in Methods. ROS levels in fibroblasts from P1 (B) and P2 (G) and age- and sex-matched 
controls were determined by loading cells with APF at intervals (1–60 minutes) following H2O2 exposure (0.5 mM, 30 minutes), with measurement of 
fluorescence by FACS analysis. (Fluorescence in the absence of APF was set arbitrarily at 1.) DNA damage, determined using an alkaline comet assay, 
was assessed in fibroblasts from P1 (C) and P2 (H) and age- and sex-matched controls in the absence and presence of exogenous H2O2 (50 μM), 
with or without addition of hOGG1, which targets oxidatively modified DNA (8-oxoGua) for excision (see Methods). Fluorescence microscopy 
images (original magnification, ×63) showing 8-oxoGua levels in fibroblasts from P1 (D) and P2 (I) and matched controls either untreated or 
exposed to H2O2 (50 μM), with DAPI staining and overlay confirming its nuclear localization, and γH2AX foci in fibroblasts from P1 (E) and P2 (J) 
and matched controls, either untreated or exposed to H2O2 (100 μM), with DAPI staining and overlay.
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At the conclusion of the present study, P2 did not exhibit cuta-
neous photosensitivity on formal testing (data not shown). His 
fibroblasts did not generate excess endogenous H2O2 (Figure 6F), 
although their exposure to oxidative stress was associated with 
increased ROS (Figure 6G), DNA damage (Figure 6, H and I), and 
γH2AX response (Figure 6J), with normal DNA repair (Supplemental 
Figure 2C). Although UV irradiation did enhance lipid peroxidation 
in his fibroblasts (Figure 7C), the amount of UV-induced DNA dam-
age was not markedly greater than that in control cells (Figure 7D).
Impaired T cell proliferation and abnormal cytokine production. Extend-
ed monitoring (over 36 months) of hematologic parameters in P1 
has documented a persistent, mild reduction in rbc and total lym-
phocyte counts (Figure 8A), with normal levels of other cell types 
(e.g., platelets, neutrophils, and monocytes). Immunophenotyp-
ing indicated no deficiency of particular lymphocyte subsets (CD4, 
CD4+CD25hi, CD4+CD45RO, CD8, CD19, CD19+CD27+, CD56) 
and normal Ig (IgG, IgM, IgA, IgE) levels (data not shown). How-
ever, the ability of his T cells to proliferate following polyclonal 
stimulation (CD3/CD28) was significantly reduced (Figure 8B), 
with such impairment not being related to lower IL-2 levels (data 
not shown). 75Se radiolabeling showed marked deficiency of 
known major T cell selenoproteins (TrxR, GPx1, and GPx4; ref. 18) 
mediating antioxidant defense (Figure 8C). Low GPx1 levels in 
rbcs (Table 1) and TrxR activity in PBMCs (Figure 8D), together 
with greater ROS accumulation in these cells (Figure 8, E and F), 
suggested more widespread loss of antioxidant defence in blood 
cells. Oxidative DNA damage secondary to reduced antioxidant 
capacity is known to include single-stranded, telomeric DNA, 
leading to accelerated telomere shortening in cells (19, 20). We 
therefore measured telomere restriction fragment (TRF) length in 
P1, finding a significant reduction in his PBMCs compared with 
controls of similar age (P1, 4.4 kb; controls, 6.2–8.1 kb; Figure 8G). 
We also documented shortening of TRF length in cells from P2 
(Supplemental Figure 2D).
LPS or TLR ligand (Pam2 or Pam3) stimulation of PBMCs from 
P1 ex vivo resulted in markedly enhanced secretion of IL-6 and 
TNF-α (Figure 9A); levels of selenoprotein S in his monocytes were 
virtually negligible (Figure 9B). His PBMCs also showed signifi-
cantly reduced IFN-γ production in response to stimulation with 
phytohemagglutinin (PHA) or with IL-12 and IL-18 (Figure 9C). 
FACS analysis of cells exposed to phorbol-12-myristate 13-acetate 
(PMA) and ionomycin localized intracellular IFN-γ deficiency to 
CD3+ and CD4+ T cells (Figure 9, D and E) and also CD8+ and 
CD3– cell populations (data not shown).
Long-term azathioprine treatment for eosinophilic colitis pre-
cluded assays of immune cell function in P2.
Increased fat mass but enhanced insulin sensitivity. Growth retarda-
tion was noted in adolescence and early childhood in P1 and P2, 
respectively. Accordingly, measurements of body composition were 
adjusted for height. Lean mass index was reduced in both cases, 
possibly reflecting underlying myopathy; in contrast, their fat 
mass index was elevated (Figure 10A). Quantification of regional 
(abdominal) body fat in P1 showed that the excess adipose tis-
sue was predominantly subcutaneous with normal visceral fat 
compared with age- and sex-matched normal subjects (Figure 10, 
B–D). Paradoxically, such heightened fat mass was associated with 
extremely favorable metabolic parameters, with low fasting insulin 
and strikingly elevated adiponectin levels (Figure 10, E and F), a 
favorable lipid profile (triglyceride, 0.5 mmol/l; NR, <1.7 mmol/l; 
HDL, 1.36 mmol/l; NR, >1.03 mmol/l), and almost negligible 
liver fat (hepatic lipid, 0.7%; NR, 0%−5%) as measured by magnetic 
resonance spectroscopy (MRS), indicating marked systemic insu-
lin sensitivity. We therefore examined insulin-mediated signaling 
in his fibroblast cells ex vivo. Both basal and insulin-dependent 
phosphorylation of ERK1/2 were markedly increased in his cells 
(Figure 10, G–I).
P2 exhibited a similar phenotype, with an elevated fat mass index 
(6.1 kg/m2; age- and sex-matched NR, 3.9–4.1 kg/m2; ref. 21), high 
circulating adiponectin (23.5 μg/ml; >97.5 centile of an 8-year-old 
normal population; ref. 22) and recurrent, fasting hypoglycemia 
with very low insulin levels.
Hearing loss. Audiometry revealed bilateral mid- to high-frequency 
sensorineural hearing loss in P1 (Supplemental Figure 3A). 
Otoacoustic emissions showed absent responses at all frequencies, 
whereas brainstem auditory evoked responses were normal (data 
not shown), indicating a defect at the cochlear level. MRI imaging 
showed normal cochlear architecture. Rotatory vertigo in this sub-
ject correlated with bilaterally diminished vestibular outputs on 
caloric testing (data not shown). P2 also exhibited sensorineural 
hearing loss at higher frequencies, but the deficit was less marked 
(Supplemental Figure 3B).
Selenoproteome profiling. Cellular siRNA-mediated SBP2 knock-
down is known to reduce transcripts of selenoprotein genes via 
NMD (23), prompting us to quantify selenoprotein gene expression 
in fibroblasts from our cases. Expression of 3 mRNAs (SELH, SELW, 
and SELT) predicted to be susceptible to NMD was significantly 
reduced (Figure 11A), which suggests that synthesis of the corre-
sponding selenoproteins is diminished, and immunoprecipitation 
of SELW from radiolabeled cells confirmed this (Figure 11B). Con-
versely, levels of other transcripts, predicted to be either susceptible 
(SELM) or refractory (SELO, SELI, and SELK) to NMD were pre-
served or even upregulated (Figure 11A). However, measurement 
of protein derived from 1 transcript in this latter category (SELI, for 
which a reliable antibody was available) showed reduced levels in P1 
(Figure 11C), which suggests that even these gene transcripts may 
not yield normal levels of protein product. Finally, expression of 
selenophosphate-synthetase 2 (SEPHS2), a Sec-containing protein 
that generates substrate for incorporation into tRNA[Ser]Sec (24), 
was reduced particularly in P2 (Figure 11C).
Discussion
We have described subjects, identified on the basis of a distinc-
tive biochemical profile (elevated T4 and low selenoprotein lev-
els), with compound heterozygous SECISBP2 defects that result in 
diminished synthesis of most known selenoproteins. The result-
ing phenotype is complex, but probably reflects 2 major patho-
genic processes: first, tissue-specific effects caused by particular 
selenoprotein deficiencies in target organs; second, consequences 
of more generalized antioxidant selenoenzyme deficiencies with 
excess cellular ROS.
The testis is highly selenium enriched, with deficiency of this 
trace element in rodents being associated with infertility (25). We 
have documented azoospermia with deficiency of 3 testis-enriched 
selenoproteins, mGPx4, TGR, and SELV, in our adult proband 
(Figure 2). mGPx4, forming cross-links with other proteins, is a 
major structural component of the mitochondrial capsule in the 
midpiece of spermatozoa (26). Murine mGPx4 inactivation causes 
male infertility (27), and reduced human seminal mGPx4 activ-
ity correlates with oligospermia (28). TGR, also highly enriched in 
spermatids, may catalyze protein disulfide bond isomerization in 
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sperm development (29). Human SELV expression is known to be 
testis restricted, but its function is unknown (3). Consistent with 
the known importance of mGPx4 and TGR in latter spermatogen-
ic stages, testicular histology in P1 showed maturation arrest, with 
preservation of early cell types (e.g., spermatogonia and spermato-
cytes) but lack of mature spermatids and spermatozoa (Figure 
2G). SEPP, acting as a source of selenium to meet tissue demand, 
has also been implicated in spermatogenesis, with SEPP-null mice 
showing abnormal sperm morphology and diminished testicular 
selenium content (30, 31). Thus, markedly reduced circulating 
SEPP levels in P1 (Figure 1B) may be an added factor contribut-
ing to his azoospermia. Although P2 was prepubertal, his serum 
SEPP (Figure 1C) and PBMC mGPx4 protein levels (Supplemental 
Figure 2A) were also low, suggesting that future spermatogenesis 
may also be compromised.
SELN is expressed in skeletal muscle, and mutations in either 
the coding region or 3′–untranslated region SECIS element of 
this gene are associated with a spectrum of myopathic disorders 
of varying clinical severity and age of onset, including RSMD1, 
desmin-related myopathy with Mallory body–like inclusions (MB-
DRM), and congenital fiber type disproportion (CFTD) (32–34). 
The musculoskeletal phenotype of our subjects showed a marked 
resemblance to SEPN1 myopathies: the pattern of muscle weak-
ness (axial) and involvement (adductors, sartorius) was very simi-
lar to RSMD1 (Figure 3, B and C); muscle histology (type 1 fiber 
predominance and occasional minicores; Figure 4, B and C) and 
reduced fibroblast SELN protein levels (Figure 4G) were compara-
ble to SEPN1 myopathy cases. A congenital myopathy resembling 
that seen in SEPN1 mutation cases was also noted in a childhood 
case described very recently (35). Collectively, these results suggest 
that a skeletal myopathy, likely mediated by SELN deficiency, is a 
feature of this disorder.
Exposure of normal human skin to ultraviolet radiation (UVR) 
is known to generate free radicals and high millimolar levels of 
H2O2 (36). Furthermore, UVR exposure upregulates GPx (37) and 
TrxR (38) activity and MSRB levels (39), protecting cells from 
oxidatively derived damage. We have documented cutaneous 
deficiency of GPx1, TrxR, and MSRB (Figure 5, B–D), together 
with increased cellular ROS (Figure 6A), membrane lipid per-
oxidation (Figure 7A), and oxidative DNA damage (Figure 6, 
C–E) in dermal fibroblasts from P1. These findings, together 
with excess lipid peroxidation and DNA damage (8-oxoGua and 
γH2AX foci) seen in SBP2-depleted cell lines (40) and enhanced 
lipid peroxidation in murine GPx4 deficiency (41, 42), substanti-
ate a link between selenoprotein deficiency and reduced cellular 
antioxidant defence. Furthermore, our observation of markedly 
Figure 7
Increased UV sensitivity in dermal fibroblasts. Untreated or α-tocopherol–treated dermal fibroblasts from P1 (A) or P2 (C) together with age- and 
sex-matched controls were exposed to UV irradiation and then loaded with redox-sensitive dye BODIPY 581/591 C11, with quantitation of percent 
cells positive for oxidized dye (FL1-H). DNA damage, assayed with the hOGG1-modified alkaline comet assay, in either untreated or UV-exposed 
dermal fibroblasts from P1 (B) and P2 (D) or control cells.
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enhanced oxidative damage following UV exposure in skin fibro-
blasts from P1 (Figure 7, A and B) provides a potential patho-
genic basis for his photosensitivity. P2 was not abnormally pho-
tosensitive by the completion of the present study, but his cells 
were less susceptible to UV-mediated DNA damage (Figure 7D) 
and generated less H2O2 (Figure 6F). It is well recognized that 
cellular accumulation of ROS can itself damage enzymes (e.g., 
catalase) that mediate its removal (43) or pathways (e.g., MSRB) 
that repair oxidized proteins (44). As P2 is still very young (age 
5 years at completion of the present study), it is conceivable that 
such cumulative ROS-mediated damage to antioxidant defence 
pathways could expose future photosensitivity.
The defective T cell proliferation we observed in P1 (Figure 8B) 
mirrors similar findings in murine T cell–specific selenoprotein 
knockout cells in which excess cellular ROS generated by T cell acti-
vation inhibits proliferation (45). Having documented deficiency 
of antioxidant selenoenzymes in T cells and increased PBMC ROS 
levels in P1 (Figure 8, C and E), we suggest that a similar mecha-
nism operates in the human context. Markedly shortened telomere 
length seen in primary cells from both cases (P1, Figure 8G; P2, 
Supplemental Figure 2D) correlated with reduced TRF length seen 
in SBP2 knockdown in human cell lines (46) and may contribute 
to the slightly reduced rbc number and lymphopenia seen in P1 
(Figure 8A). Thus, the degree of telomere shortening in his PBMCs 
is comparable to that seen in subjects with TERT mutations, which 
is associated with aplastic anemia (47); similarly, mice engineered 
to have short telomeres exhibit hematologic abnormalities, includ-
ing low blood counts and impaired lymphocyte proliferation (48). 
Intriguingly, shortened telomere length in T cells has also been 
specifically associated with connective tissue disorders, includ-
ing lupus, RA, and scleroderma (49, 50); in this context, we note 
that P1 has marked Raynaud disease, albeit without other clinical 
or serological features of a connective tissue disorder. Although 
neither proband was overtly immunodeficient, telomere erosion 
is most likely to limit self-renewal of highly proliferative cell com-
partments (e.g., bone marrow), and it is conceivable that added 
insults (e.g., viral infection and drug toxicity) could compromise 
hemopoiesis or immune function in these cases.
Figure 8
Impaired T cell proliferation, with reduced antioxidant defense and telomere shortening, in PBMCs. (A) Persistently reduced peripheral rbc 
and lymphocyte counts from P1 over a 36-month period. (B) Impaired T cell proliferation in P1. Following stimulation of PBMCs from P1 and 
his brother, FACS analysis shows dilution of the intracellular dye (CFSE) in CD3+ T cells. (C) Selenoprotein levels in 75Se-labeled T cells, with 
35S-Met labeling of cells confirming comparable protein loading, in P1 and an age- and sex-matched control subject. Arrows denote positions 
of bands corresponding to specific selenoproteins (TrxR, GPx1, GPx4, and Sep15). (D) TrxR activity in PBMCs from P1 compared with his 
brother and an age- and sex-matched control subject. (E) ROS production in PBMCs from P1, his mother, and an age- and sex-matched control, 
determined as described for dermal fibroblasts in Figure 6B. (F) ROS levels in RBCs from P1 (each symbol is an independent determination on 
a different occasion) or control subjects (each symbol is a measurement from a different individual). (G) Telomeric shortening in PBMCs of P1. 
Average telomere length (kb) in DNA from PBMCs of P1, his brother (Br), and 3 age- and sex-matched control subjects, determined by Southern 
blotting using a telomere-specific probe. Mw, molecular weight size marker.
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LPS-induced TNF-α secretion from macrophages cultured in sele-
nium-depleted medium is markedly enhanced (51). A population 
study has correlated circulating TNF-α/IL-6 levels with a SNP in the 
SELS gene and siRNA knockdown of SELS in macrophages enhances 
LPS-induced TNF-α and IL-6 secretion (52). We therefore suggest 
that the observed reduction in SELS levels (Figure 9B) accounted 
for the excess TNF-α and IL-6 production by PBMCs in P1 (Figure 
9A). Whether particular selenoprotein deficiencies mediate defective 
IFN-γ production by his immune cells remains to be elucidated.
Based on previous observations of insulin resistance in subjects 
with SEPN1-related myopathy (53), we were surprised that both 
probands were markedly insulin sensitive, particularly in associa-
tion with enhanced fat mass. Interestingly, increased fat mass was 
also a feature in the recently described childhood case (35). Both 
probands exhibited deficiencies of antioxidant selenoenzymes (e.g., 
GPx1; Table 1 and Figure 5B) and elevated cellular ROS. In this con-
text, GPx1-null mice with elevated ROS levels have recently been 
shown to be more insulin sensitive (54). Elevated ROS levels enhance 
ERK phosphorylation in a murine Sirt-3 deficiency model (55), and 
a similar mechanism could account for the increased pERK levels 
observed in fibroblasts from P1 (Figure 10, G and H). There is also 
evidence for cross-talk between ERK and Akt insulin signaling path-
ways (56). It is therefore plausible that increased ROS and elevated 
pERK levels, mediating greater tissue insulin responsiveness, con-
tribute to the enhanced insulin sensitivity in both probands.
Although hearing loss is a feature in dio2-null mice (57), the thy-
roid hormone profile in both P1 and P2 and other published cases 
is more congruent with combined partial deficiency of all deiodin-
ases (12, 58). ROS are known to induce cochlear damage, which 
can be limited by antioxidant treatment (59), and GPx1-null mice 
exhibit susceptibility to noise-induced hearing loss (60). ROS-
mediated damage can also be cumulative (61), and this alternative 
mechanism for hearing loss might account for our observation 
that auditory deficit was more severe in P1 (Supplemental Figure 
3A), who is older than P2 (Supplemental Figure 3B).
Overall, we suggest that some phenotypes (e.g., azoospermia and 
myopathy) in this disorder are mediated by tissue-specific selenopro-
tein deficiencies; other features (e.g., cutaneous photosensitivity and 
impaired T cell proliferation) are likely mediated by impaired cellu-
lar antioxidant defense, reflecting the high oxidative stress to which 
these tissues are subjected with sun exposure and antigenic stimula-
tion, respectively. Some phenotypes (e.g., photosensitivity and hear-
ing loss) may be age-dependent, reflecting cumulative ROS-mediated 
damage; it is therefore conceivable that other pathologies linked to 
oxidative damage (e.g., neoplasia, neurodegeneration, and premature 
aging) may only manifest with time. Future identification of other 
affected subjects, by biochemical screening of cases of idiopathic male 
infertility, SEPN1-like myopathies, or photosensitivity, for example, 
may delineate phenotypes that are more variably expressed. Thus, it 
is tempting to speculate that the biopsy-proven colitis of unknown 
etiology in P2 could be related to ileocolonic inflammation seen in 
compound GPx1/GPx2 knockout mice (62), although P1 has no 
gastrointestinal problems. Conversely, whereas selective depletion 
of selenoproteins in murine osteochondroprogenitor cells results in 
epiphyseal abnormalities and chondronecrosis (63), radiologic skel-
etal survey and bone mineral density in P1 were normal (data not 
shown). Further cases may also reveal additional phenotypes linked 
to deficiencies of selenoproteins of unknown function.
Figure 9
Abnormal cytokine production from 
PBMCs. (A )  IL-6 secret ion in 
response to LPS, Pam2, and Pam3 
exposure (24 h), and TNF-α secre-
tion in response to LPS and LPS plus 
IFN-γ exposure (12 h), were assayed 
in supernatants of PBMCs from P1 
and an age-matched control subject. 
(B) Whole cell lysates from CD14+ 
monocytes were Western blotted for 
SELS (arrow), with actin as a loading 
control. The control subject was age- 
and sex-matched. (C) PBMCs of P1 
and an age-matched control subject 
were stimulated either by PHA or by 
IL-12 and IL-18, and IFN-γ respons-
es were assayed at 48 h. (D and E) 
Intracellular IFN-γ levels in CD3+ 
and CD4+ cell populations derived 
from PBMCs exposed to PMA and 
ionomycin were determined by FACS 
analysis (see Methods) in P1 and a 
group of age- and sex-matched con-
trol subjects. Each symbol denotes 1 
individual; red symbol denotes P1.
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With regard to possible therapies, T3 treatment is benefi-
cial in childhood cases with subnormal T3 levels, as has been 
documented by others (12) and us in the case of P2, although a 
plateau in his height and weight suggests that growth retarda-
tion may not be solely related to thyroid status (Supplemental 
Figure 4). Although trials of selenium supplementation of 
previous cases raised circulating levels of the trace element, 
defective selenoprotein synthesis was not corrected (64). As 
excess lipid peroxidation in cells from our cases was amelio-
rated by α-tocopherol exposure (Figure 7, A and C), we sug-
gest that, as has been advocated in SEPN1-related myopathy 
(65), a trial of antioxidant treatment (e.g., n-acetyl cysteine, 
vitamin E/α-tocopherol, and ascorbic acid) in this disorder 
might represent a rational alternative.
Figure 10
Increased fat mass but enhanced insulin sensitivity. (A) Anthropometric measures and body composition data in P1 and P2 are shown as 
z scores, relative to an age- and sex-matched normal reference population. (B) Quantitation of visceral (green) and subcutaneous (red) abdomi-
nal fat from cross-sectional magnetic resonance imaging scans in P1 and an age- and sex-matched control subject. (C–F) Abdominal visceral 
(C) and subcutaneous (D) fat in P1 (red symbol) and age- and sex-matched normal subjects (black symbols; n = 320) measured by ultrasound 
scan; circulating, fasting adiponectin (E) and insulin (F) levels in P1 (red symbol) and age- and sex-matched normal subjects (black symbols; 
n = 180). Normal individuals were subjects recruited to a local (MRC, Fenland) population-based cohort study. (G–I) Primary fibroblasts from P1 
and an age- and sex-matched control subject were exposed to varying insulin concentrations. (G) Representative Western blot showing pAKT 
and pERK1/2 levels with calnexin as loading control. (H and I) Quantification of pERK1/2 and pAKT levels.
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Methods
All procedures were undertaken either with approval from the Cambridge 
Research Ethics Committee or as clinically indicated investigations, and 
prior informed consent was obtained from all participating study subjects.
Sequencing of SECISBP2 gene
For each proband, exons 1–17 of the SECISBP2 gene, intron-exon boundar-
ies, and 900 bp of the promoter region were amplified using specific prim-
ers (Supplemental Table 1) and sequenced (3100 AVANT; ABI). RNA from 
PBMCs was reverse transcribed to generate SECISBP2 cDNAs, which were 
PCR amplified and sequenced.
SBP2 mutant characterization
The T668ΔT and C691R mutations were introduced into the previously 
described SBP2 WT minigene (10) using the Quick-Change site-directed 
mutagenesis kit (Stratagene) and the following primers: T668ΔT for-
ward, 5′-GAATTTACCACACTGGACTTCCTGAACTGCAAGGTGC-3′; 
T668ΔT reverse, 5′-GCACCTTGCAGTTCAGGAAGTCCAGTGTGGTA-
AATTC-3′; C691R forward, 5′-CTGAAGCTCAAAAAACTGAAACGTGT-
CATTATTTCTCCC-3′; C691R reverse, 5′-GGGAGAAATAATGACAC-
GTTTCAGTTTTTTGAGCTTCAG-3′. Plasmid integrity was verified by 
sequencing. Minigenes were transiently transfected into human embry-
onic kidney HEK293T cells using 2 μg of plasmid DNA per well of a 6-well 
plate and the FuGENE 6 transfection reagent (Roche Diagnostics). Cells 
were lysed 48 hours after transfection and analyzed by Western blotting 
using antibodies to SBP2 as previously described (24). For protein stability 
assessment, 293T cells were transfected with the SBP2 WT or C691R con-
structs, and 24 hours later, the proteosome inhibitor MG132 (10 μM) was 
added to the cells in culture and incubated for the time indicated.
Biochemical measurements
Plasma selenium was measured by inductively coupled plasma mass spec-
trometry (ICPMS; Thermo Elemental). We measured rbc GPx activity by 
enzymatic analysis (Ransel) as described previously (66). Serum free T4, 
free T3, and TSH together with plasma insulin and adiponectin were mea-
sured by 2-step, time-resolved immunofluorometric (DELFIA) assays and 
reverse T3 by radioimmunoassay (Biocode).
Radiolabeled selenoprotein studies
PBMCs were isolated by Ficoll gradient centrifugation. T cells were isolat-
ed by immunomagnetic cell separation as specified by the manufacturer’s 
protocol (Miltenyi Biotec), and their purity assessed by flow cytometry was 
greater than 90%. Cells were incubated either in standard medium (DMEM 
plus 10% FBS) supplemented with 10 μCi 75Se (University of Missouri 
research reactor facility) or in methionine-free medium supplemented with 
50 μCi 35S-Met (Perkin Elmer), harvested after 48 hours, and analyzed by 
SDS-PAGE and autoradiography as described previously (24).
Histopathology and Western blot assays
Histopathology. Lateral quadriceps muscle biopsy was subjected to conven-
tional histochemical staining. Skin biopsy and testis tissue were forma-
lin-fixed, paraffin processed, and sectioned for H&E and IHC studies as 
follows. IHC of testis was performed using anti-GPx4 (rabbit polyclonal 
sc-50497, Santa Cruz Biotechnology at 1:150 dilution), anti-TGR (rab-
bit polyclonal, gift from V. Gladyshev, Brigham and Women’s Hospital, 
Boston, Massachusetts, USA, at 1:5,000 dilution), and anti-SELV (goat 
polyclonal N-14, Santa Cruz Biotechnology at 1:50 dilution) antibodies. 
IHC of skin was performed using an anti-GPx1 antibody (rabbit polyclonal 
NBP1-18664, Novus Biologicals at 1:900 dilution).
Western blotting and immunoprecipitation. PBMCs or dermal fibroblast cells, 
lysed in RIPA buffer containing a protease inhibitor cocktail, or seminal 
plasma were analyzed by SDS-PAGE and Western blotting using spe-
cific antibodies as follows: SBP2 (rabbit polyclonal, ref. 24); GPx4 (goat 
polyclonal EB07316, Everest Biotech); TGR (rabbit polyclonal, gift from 
V. Gladyshev, ref. 29); SELV (goat polyclonal N-14, Santa Cruz Biotech-
nology); SELN (rabbit polyclonal ab137, Abcam, ref. 67); MSRB (mouse 
monoclonal ab66061, Abcam); SELS (rabbit polyclonal ab58656, Abcam); 
SELI (mouse polyclonal AO1, Abnova); SEPHS2 (rabbit polyclonal I-23, 
Santa Cruz Biotechnology). Extracts of fibroblasts, radiolabeled with 
10 μCi 75Se as described above, were immunoprecipitated with a SELW 
antibody (rabbit polyclonal 233,833; antibodies-online) and analyzed by 
SDS-PAGE, with 35S-Met–labeled extracts as a loading control.
Thioredoxin reductase activity in PBMCs and skin. Skin tissue or PBMCs from 
P1, his sibling, and normal controls were homogenized in buffer (50 mM 
Tris; 1 mM EDTA; protease inhibitor cocktail, Roche Diagnostics), soni-
cated, and then centrifuged to generate supernatants. TrxR activity in cell 
lysates was measured by a sensitive method, based on assay of thioredoxin-
dependent reduction of fluorescent-labeled insulin substrate (68).
ROS, lipid peroxidation, and DNA damage assays
ROS in rbcs. Briefly, whole blood was diluted in PBS to a concentration of 
approximately 1 × 106 erythrocytes/ml and incubated with 1 μM 5-(and-6)- 
chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester 
(CM-H2DCFDA, Invitrogen) or an equivalent volume of DMSO at room temper-
ature for 30 minutes in the dark. After incubation, CM-H2DCFDA–loaded cells 
were washed and resuspended in PBS, and fluorescence was measured using 
a LSR II flow cytometer (BD Biosciences, FL1 channel). Each experiment was 
performed in duplicate using blood cells sampled on 4 separate occasions.
Figure 11
Altered expression of selenoproteome members in P1 
and P2. (A) Relative mRNA levels of 7 different seleno-
proteins, whose physiological roles remain to be defined, 
in fibroblasts from a control subject, P1, and P2, mea-
sured by qPCR. Red indicates higher, and blue lower, 
levels of gene expression relative to the control (uniformly 
designated yellow). (B) Autoradiographs of 75Se-labeled 
fibroblast cell lysates from P1 and P2 and age- and sex-
matched controls, immunoprecipitated with anti-SELW 
antibody; 35S-Met–labeled cells are shown as a loading 
control. (C) Western blotting showing variably reduced 
expression of SELI and SEPHS2 in fibroblasts from P1 
and P2 compared with age- and sex-matched controls, 
with actin loading control.
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ROS assays in PBMCs and fibroblasts. PBMCs diluted in PBS (5–10 × 106 
cells/ml) or dermal fibroblasts (50 × 103 cells/well in a 24-well plate) 
were incubated with either 2 μM 3′-(p-aminophenyl)fluorescein (APF) 
or methyl acetate (solvent control) for 30 minutes (PBMCs, room tem-
perature; fibroblasts, 37°C) in the dark, washed in PBS, and analyzed by 
flow cytometry (FACScalibur, BD Biosciences, FL1 channel) to measure 
baseline ROS levels. Cells were also preincubated with H2O2 (0.5 mM, 30 
minutes) before being loaded with APF, and fluorescence was measured 
over a time course of 1–60 minutes.
Endogenous H2O2 generation by fibroblasts. Extracellular H2O2 accumulation 
by dermal fibroblasts (cultured in HAM’s F12 plus 20% FBS), was assayed 
by addition of Amplex Red (Invitrogen) to the medium and measurement 
of fluorescence according to the manufacturer’s protocol. Values were 
adjusted for viable cell numbers quantified by an MTT assay.
Lipid peroxidation. Dermal fibroblasts (105 cells), incubated in medium 
(DMEM plus 10% FCS) with or without α-tocopherol (1 mM, Sigma-
Aldrich), were exposed to UVA (365 nm, 1 J/cm2) for 15 minutes, then 
loaded with 1 μM BODIPY 581/591 C11 (Invitrogen), and fluorescence 
was monitored by flow cytometry on channels FL1-H at 530 nm and 
FL2-H at 585 nm.
Assays of DNA damage and base excision repair. DNA damage and repair 
were assessed using the human 8-oxoguanine DNA glycosylase 1–modi-
fied (hOGG1-modified) alkaline comet assay. Assay in the absence of 
hOGG1 enables the detection of SSBs and, at pH >13, alkali-labile sites, 
which may include apurinic/apyrimidinic (AP) sites, oxidized AP sites, 
and certain modified bases (69). Assay parameters with use of hOGG1 
were as optimized previously (70), with the remaining conditions also as 
described before (71). All procedures were carried out under subdued light 
to minimize adventitious DNA damage. Dermal fibroblasts (~12 × 104 
cells), immobilized in 0.6% low–melting point agarose, on precoated (1% 
agarose) slides, were lysed in ice-cold buffer (10 mM Tris, 100 mM EDTA, 
2.5 M NaCl, 1 % Triton X-100), incubated with hOGG1 (3.2 U/ml, 37°C 
for 45 minutes), and then electrophoresed in alkaline buffer (300 mM 
NaOH, 1 mM EDTA, pH ≥13). Propidium iodide–stained cells (at least 
100 cells per sample) were visualized by fluorescence microscopy, and 
image analysis software (Comet Assay IV, Perceptive Instruments) was 
used to calculate the percentage of damaged DNA in the tail of the comet 
for each cell. The antioxidant capacity of cells was determined by quan-
tifying DNA damage by hOGG1-modified Comet assay (as described 
above) immediately following their exposure to H2O2 challenge (50 μM 
for 30 minutes) or UVA (10 J/cm2).
8-oxoGua levels and γH2AX foci in fibroblasts. Dermal fibroblasts grown 
on coverslips were processed as described previously (72). For 8-oxoGua 
staining, cells were incubated in the absence or presence of 50 μM H2O2 
for 30 minutes, fixed (methanol/acetone), and treated with 0.05M HCl 
and RNAase (100 mg/ml). Alkali DNA denaturation (0.15M NaOH) and 
proteinase K digestion (5 mg/ml) steps were followed by incubation with 
anti–8-oxoGua antibody (Millipore) at 1:250 dilution. For visualization of 
γH2AX foci, fibroblasts were incubated in the absence or presence of 100 μM 
H2O2 for 30 minutes, fixed (95% ethanol and 5% acetic acid), and incubated 
with anti–phospho-Histone H2AX (Ser139) antibody (Millipore) at 1:500 
dilution. In both protocols, cells were counterstained with DAPI and visu-
alized by fluorescence microscopy.
Telomere restriction fragment length assay
Telomere length was determined using the Telo TAGGG telomere length 
assay kit (Roche). Briefly, DNA from either buccal mucosal cells or PBMCs 
was digested with HinfI and RsaI, separated by gel electrophoresis, South-
ern blotted, and hybridized with a telomere-specific digoxigenin-labeled 
probe, as described by the manufacturer.
T cell proliferation and cytokine production
T cell proliferation assays. PBMCs, isolated by Ficoll gradient centrifugation, 
were incubated in plates coated with anti-CD3 (1 μg/ml, BD Biosciences — 
Pharmingen 550368), washed with medium (RPMI plus 10% autologous 
serum), then dye labeled (5 μM CFSE, Invitrogen) and plated (1 × 106 cells/well) 
with either medium alone (unstimulated cells) or medium supplemented 
with anti-CD28 monoclonal antibody (1 μg/ml, gift from H. Waldmann, 
Oxford University, Oxford, United Kingdom). After 5–6 days, cells were 
labeled with anti-CD3 APC antibody (Serotec MCA463APC) and analyzed 
by FACS (BD FACSCalibur flow cytometer). CD3+ cells were identified 
within a gated lymphocyte population, and CFSE staining was visualized 
using a histogram plot (MODFIT LT 3.0 PC software, Verity Software 
House). The parental population was identified using unstimulated cells, 
and anti-CD3/CD28–induced cell proliferation was analyzed.
Cytokine profiling of PBMCs. PBMCs isolated by Ficoll gradient centrifu-
gation were plated (1 × 106 cells/ml, 96-well plates) and exposed to stimu-
latory agents as follows: Pam2CSK4 and Pam3CSK4 (EMC microcollec-
tions and List biological laboratories/Quadratech, 0.4 μg/ml, blocked with 
40 μg/ml Polymyxin B [Fluka]); LPS (from S. Minnesota E595, 1 μg/ml); 
PHA-P (10 μg/ml, Sigma-Aldrich); IL-12 (R&D Systems, 20 μg/ml); IL-18 
(R&D Systems, 50 μg/ml); and IFN-γ (2 × 104 U/ml, Immukin, Boehringer 
Ingelheim). Cell supernatants were harvested at different time points to mea-
sure cytokine levels (12 hours, TNF-α and IL-12; 24 hours, IL-6; 48 hours, 
IFN-γ). Cytokine levels were determined by either standard ELISA (IFN-γ, 
Pelikine, CLB Holland) or by Luminex (Bioplex, Biorad) technology-based 
assays (TNF-α and IL-6, R&D Systems) as specified by the manufacturers.
Intracellular cytokine assays. PBMCs from P1 and normal controls were 
stimulated for 5 hours with PMA (50 ng/ml, Sigma-Aldrich) and iono-
mycin (1 μg/ml, Sigma-Aldrich) in the presence of Golgi stop (BD Biosci-
ences — Pharmingen). Cells were then stained with RPE-Cy5–conjugated 
anti-CD3 and APC-conjugated anti-CD4 antibodies (BD Biosciences), 
fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences — 
Pharmingen), and stained with Pacific Blue–conjugated antibody to IFN-γ 
(eBioscience). Data were acquired on FACS Canto II and analyzed with 
FACSDiva software (BD Biosciences).
Insulin signaling pathway
Fibroblasts from P1 and control cells were serum deprived (16 hours), exposed 
to varying concentrations of insulin (5 minutes), lysed, and analyzed by 
Western blotting using specific antibodies as follows: pERK1/2 (T202/T204) 
(mouse monoclonal 9106, Cell Signalling); pAKT (S473) (rabbit monoclonal 
9271, Cell Signalling); calnexin (rabbit polyclonal ab 13504, Abcam).
Quantitative real-time PCR assays of selenoprotein expression
RNA (100 ng) from fibroblasts was reverse transcribed using a high-capac-
ity cDNA archive kit (Applied Biosystems). Taqman assays (Applied Bio-
systems) used probes listed in Supplemental Table 2. The comparative Ct 
method was used to quantify transcripts and normalize to cyclophilin A 
expression levels. Additional software was used to normalize data to expres-
sion levels in control cells (GeneSpring 7.2 software, Agilent) and generate 
heatmaps (PARTEK genomics suite, Partek).
Statistics
For all figures, error bars indicate mean ± SEM of at least 3 independent 
determinations. Statistical analyses were performed using 2-tailed Stu-
dent’s t test (Figure 5C; Figure 7, A and C; Figure 8, D and F; and Figure 9, 
A, C, and E); 2-way ANOVA (Figure 6, A, B, F, and G; Figure 8E; and Figure 
10H) with post-hoc Bonferroni correction for multiple comparisons where 
appropriate; or Mann-Whitney tests (Figure 6, C and H, and Figure 7, B 
and D). A P value less than 0.05 was considered significant.
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